ClinicalTrials.gg
CompletedNCT02446912Updated Jan 12, 2023Results posted

Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

A Phase 3 interventional study of Anifrolumab and Placebo in Active Systemic Lupus Erythematosus, sponsored by AstraZeneca. Completed at 146 sites in 18 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-01-12.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.

Enrollment
3rd of 20
460 · median 159
Started
2015
with 1 other
Phase 3
9 of 20
4 open now
Registered
4th of 20
by date
Lead sponsor
15 of 20
AstraZeneca

Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 3rd largest by enrollment, is one of 2 that started in 2015, is one of 9 in phase 3, and was the 4th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About anifrolumab

anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

Read the detailed description

This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. The study will be performed in adult subjects aged 18 to 70 years of age.

03

Conditions studied

  • Active Systemic Lupus Erythematosus

Keywords

  • Active Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 through 70 years at the time of screening
  2. Diagnosis of paediatric or adult SLE with a diagnosis of SLE according to the ACR 1982 revised criteria ≥24 weeks prior to signing the form (ICF)
  3. Currently receiving at least 1 of the following:

    1. Where prednisone is the single standard of care medication (ie, the subject is not concurrently receiving any medication listed in inclusion criterion 3(c)), a dose of oral prednisone ≥7.5 mg/day but ≤40 mg/day (or prednisone equivalent) for a minimum of 8 weeks prior to Day 1. In addition, the dose of oral prednisone or prednisone equivalent the subject is taking must be stable for a minimum of 2 weeks prior to randomisation.
    2. Where prednisone is not the single standard of care medication (ie, the subject is concurrently receiving at least one medication listed in inclusion criterion 3(c)), a dose of oral prednisone (≤40 mg/day) (or prednisone equivalent) for a minimum of 2 weeks prior to signing of the ICF. In addition, the dose of oral prednisone or prednisone equivalent the subject is taking must be stable for a minimum of 2 weeks prior to randomisation.
    3. Any of the following medications administered for a minimum of 12 weeks prior to signing the informed consent, and at a stable dose for a minimum of 8 weeks prior to signing the informed consent through Day 1:

    (i) Azathioprine ≤200 mg/day (ii) Antimalarial (eg, chloroquine, hydroxychloroquine, quinacrine) (iii) Mycophenolate mofetil ≤2 g/day or mycophenolic acid ≤1.44 g/day (iv) Oral, subcutaneous (SC), or intramuscular methotrexate ≤25 mg/week (v) Mizoribine ≤150 mg/day

  4. Fulfils at least 4 of the 11 ACR modified 1982 classification criteria for SLE, at least 1 of which must be:

    1. Positive antinuclear antibody (ANA) test at screening by immunofluorescent assay (IFA) at the central laboratory with titre ≥1:80; OR
    2. Anti-dsDNA antibodies at screening elevated to above normal (including indeterminante), as per the central laboratory; OR
    3. Anti-Smith (anti-Sm) antibody at screening elevated to above normal as per the central laboratory.
  5. At Screening, Disease Activity Adjudication Group confirmation of:

    SLEDAI-2K Criteria: SLEDAI-2K score ≥6 points and "Clinical" SLEDAI-2K score ≥4 points. The "Clinical" SLEDAI-2K is the SLEDAI-2K assessment score without the inclusion of points attributable to any urine or laboratory results including immunologic measures.

  6. Must not have active or latent TB on either chest radiograph or by quantiferon gold test
  7. Day 1 "Clinical" SLEDAI-2K score ≥4 points
  8. OCS dose stable for at least 2 weeks prior to randomisation
  9. Stable SLE SOC treatment at the time of randomisation
  10. Women of must have a negative serum β-hCG test and negative urine pregnancy test at randomisation (Day 1) prior to administration of product

Exclusion criteria

Exclusion Criteria:

  1. Receipt of any product (small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater
  2. Receipt of any of the following:

    (a) Intra-articular, intramuscular or IV glucocorticosteroids within 6 weeks prior to Day 1

  3. History of, or current diagnosis of, a non SLE-related vasculitis syndrome.
  4. Active severe or unstable neuropsychiatric SLE
  5. Active severe SLE-driven renal disease
  6. Diagnosis (within 1 year of signing the ICF) of mixed connective tissue disease or any history of overlap syndromes of SLE or SSc.
  7. History of, or current, inflammatory joint or skin disease other than SLE
  8. History of any non-SLE disease that has required treatment with oral or parenteral for more than 2 weeks within the last 24 weeks prior to signing the ICF
  9. Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the subject to infection, or a positive result for (HIV) infection confirmed by central laboratory at screening. Subjects refusing HIV testing during the screening period will not be eligible for study participation
  10. Confirmed positive test for or
  11. Any severe herpes infection at any time prior to Week 0 (Day 1)
  12. Opportunistic infection requiring hospitalisation or intravenous antimicrobial treatment within 3 years prior to randomization
  13. History of cancer, apart from:

    1. Squamous or basal cell carcinoma of the skin that has been successfully treated
    2. Cervical cancer in situ that has been successfully treated
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
460 participants (actual)

Study arms

  • Experimental
    Anifrolumab - higher dose

    Anifrolumab

    Biological: Anifrolumab

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    Anifrolumab - lower dose

    Anifrolumab

    Biological: Anifrolumab

Interventions

  • BiologicalAnifrolumab

    Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses

  • DrugPlacebo

    Placebo IV administration every 4 weeks from Week 0 to Week 48

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)

    SRI(4) was defined as meeting all of the following criteria: Reduction from baseline of ≥4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) No new organ systems affected, defined by 1 or more British Isles Lupus Assessment Group (BILAG-2004) A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.

    Time frame: Week 52

Secondary outcomes

  1. Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Original Analysis With Restricted Medication Rules)

    SRI(4) was defined as meeting all of the following criteria: Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.

    Time frame: Week 52

  2. Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Original Analysis With Restricted Medication Rules)

    Maintained OCS reduction was defined by meeting all the following criteria: Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.

    Time frame: Week 52

  3. Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Original Analysis With Restricted Medication Rules)

    50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all of the following criteria: Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold before assessment.

    Time frame: Week 12

  4. Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Original Analysis With Restricted Medication Rules)

    SRI(4) was defined as meeting all of the following criteria: Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified threshold.

    Time frame: Week 24

  5. Annualized Flare Rate

    A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment.

    Time frame: Baseline to Week 52

  6. Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Original Analysis With Restricted Medication Rules)

    A BICLA responder was achieved if all of the following criteria was met: All criteria related to SRI(4) (please see primary endpoint) plus: Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.

    Time frame: Week 52

  7. Number of Participants Reporting One or More Adverse Events (AE)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs.

    Time frame: Baseline to End of Trial (Maximum of 60 weeks)

  8. Number of Participants Reporting One or More Adverse Events of Special Interest (AESI)

    An AESI is an AE of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by the Investigator to the Sponsor/Sponsor's delegate. An AESI may be serious or nonserious. The events of interest are serious infections, including non opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, TB (including latent TB), influenza, vasculitis (non-SLE), and MACE (including stroke, MI, or cardiovascular death). AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

    Time frame: Baseline to End of Trial (Maximum of 60 weeks)

  9. Number of Participants With Markedly Abnormal Vital Signs

    Vital signs included oral temperature, blood pressure (BP), pulse rate, and respiratory rate. Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

    Time frame: Baseline to End of Trial (Maximum of 60 weeks)

  10. Number of Participants With Markedly Abnormal Physical Examinations

    Physical examinations included height and weight. Participants were weighed at each study visit and any medically significant changes were reported. Physical examination values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

    Time frame: Baseline to End of Trial (Maximum of 60 weeks)

  11. Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Scores

    ECGs documented the date, time, heart rate, QRS duration, PR interval, RR interval, QT, and corrected QT interval, which were calculated using the Fridericia formula. The investigator judged the overall interpretation as normal or abnormal, and if abnormal it was decided as to whether or not the abnormality was clinically significant or not clinically significant.

    Time frame: Baseline to Week 52

  12. Number of Participants With Mild To Moderate Lupus Flare Evaluated by Modified Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI Flare Index

    The modified SELENA flare index was completed by the Investigator or delegated/qualified physician. Assessment of flares were scored in comparison to the participant's previous visit and should only include findings which, in the opinion of the Investigator, are due to systemic lupus erythematosus (SLE) disease activity within that timeframe. Flare was defined as any 1 criterion present in either the Mild/Moderate Flare or Severe Flare categories. Number of flares were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

    Time frame: Baseline to End of Trial (Maximum of 60 weeks)

  13. Number of Participants With Markedly Abnormal Laboratory Tests

    Laboratory tests were collected at central clinical laboratories and included hematology, serum chemistry and urinalysis tests. Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

    Time frame: Baseline to End of Trial (Maximum of 60 weeks)

  14. Number of Participants With Suicidal Ideation or Behaviour Assessed Via the Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Number of participants with suicidal ideation or behavior was defined as the number of participants who answered "yes" at any time during the treatment period (Baseline to Week 52) to one of the 10 categories: Category 1: Wish to be dead Category 2: Non-specific active suicidal thoughts Category 3: Active suicidal ideation with any methods (not plan) without intent to act Category 4: Active suicidal ideation with some intent to act, without specific plan Category 5: Active suicidal ideation with specific plan and intent Category 6: Preparatory acts or behavior Category 7: Aborted attempt Category 8: Interrupted attempt Category 9: Actual attempt (non-fatal) Category 10: Completed suicide

    Time frame: Baseline to Week 52

  15. Change From Baseline in Personal Health Questionnaire Depression Scale-8 (PHQ-8) Score

    PHQ-8 is a 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQ-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms. A negative change from baseline score indicates improvement in symptoms.

    Time frame: Baseline to Week 52

07

Results

Posted Dec 5, 2019

Participant flow

Participants took part in the trial at 123 sites in 18 countries worldwide.

Participant flow — Overall Study
MilestoneAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Started93180184
Participants who completed week 5280153157
Completed75145149
Not completed183535
Withdrew: Adverse event3135
Withdrew: Condition under investigation worsened011
Withdrew: Study-specific withdrawal criteria100
Withdrew: Lack of efficacy147
Withdrew: Lost to follow-up002
Withdrew: Severe non-compliance to protocol101
Withdrew: Withdrawal by subject101515
Withdrew: Miscellaneous224

Outcome measures

PrimaryNumber of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)

SRI(4) was defined as meeting all of the following criteria: Reduction from baseline of ≥4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) No new organ systems affected, defined by 1 or more British Isles Lupus Assessment Group (BILAG-2004) A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)356574
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.412 (Nominal p-value) · Mean difference (final values): -4.2 · 95% CI -14.2 to 5.8
  • Anifrolumab 150 mg vs Placebo · Mean difference (final values): -2.6 · 95% CI -14.7 to 9.6
Post-hocNumber of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Post-Hoc Analysis With Revised Restricted Medication Rules)

SRI(4) was defined as meeting all of the following criteria: Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc allowed threshold. Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Post-Hoc Analysis With Revised Restricted Medication Rules)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Post-Hoc Analysis With Revised Restricted Medication Rules)458479
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.455 (Nominal p-value) · Mean difference (final values): 3.9 · 95% CI -6.3 to 14.1
  • Anifrolumab 150 mg vs Placebo · Mean difference (final values): 5.5 · 95% CI -6.7 to 17.8
SecondaryNumber of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Original Analysis With Restricted Medication Rules)

SRI(4) was defined as meeting all of the following criteria: Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Original Analysis With Restricted Medication Rules)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Original Analysis With Restricted Medication Rules)305359
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.549 (Nominal p-value) · Mean difference (final values): -3.4 · 95% CI -14.4 to 7.6
Post-hocNumber of Participants Who Achieved an Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Post-Hoc Analysis With Revised Restricted Medication Rules)

SRI(4) was defined as meeting all of the following criteria: Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold. Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Achieved an Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Post-Hoc Analysis With Revised Restricted Medication Rules)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants Who Achieved an Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Post-Hoc Analysis With Revised Restricted Medication Rules)407163
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.261 (Nominal p-value) · Mean difference (final values): 6.4 · 95% CI -4.8 to 17.7
SecondaryNumber of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Original Analysis With Restricted Medication Rules)

Maintained OCS reduction was defined by meeting all the following criteria: Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Original Analysis With Restricted Medication Rules)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Original Analysis With Restricted Medication Rules)174233
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.180 (Nominal p-value) · Mean difference (final values): 8.9 · 95% CI -4.1 to 21.9
Post-hocNumber of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Post-Hoc Analysis With Revised Restricted Medication Rules)

Maintained OCS reduction was defined by meeting all of the following criteria: Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold. Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medication confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Post-Hoc Analysis With Revised Restricted Medication Rules)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Post-Hoc Analysis With Revised Restricted Medication Rules)245033
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.013 (Nominal p-value) · Mean difference (final values): 16.7 · 95% CI 3.5 to 29.8
SecondaryNumber of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Original Analysis With Restricted Medication Rules)

50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all of the following criteria: Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold before assessment.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Original Analysis With Restricted Medication Rules)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Original Analysis With Restricted Medication Rules)152414
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.054 (Nominal p-value) · Mean difference (final values): 17.0 · 95% CI -0.3 to 34.3
Post-hocNumber of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Post-Hoc Analysis With Revised Restricted Medication Rules)

50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all the following criteria: Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment. Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medication confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Post-Hoc Analysis With Revised Restricted Medication Rules)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Post-Hoc Analysis With Revised Restricted Medication Rules)162514
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.034 (Nominal p-value) · Mean difference (final values): 18.7 · 95% CI 1.4 to 36.0
SecondaryNumber of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Original Analysis With Restricted Medication Rules)

SRI(4) was defined as meeting all of the following criteria: Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified threshold.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Original Analysis With Restricted Medication Rules)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Original Analysis With Restricted Medication Rules)347475
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.905 (Nominal p-value) · Mean difference (final values): 0.6 · 95% CI -9.4 to 10.6
Post-hocNumber of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Post-Hoc Analysis With Revised Restricted Medication Rules)

SRI(4) was defined as meeting all of the following criteria: Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc allowed threshold. Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Post-Hoc Analysis With Revised Restricted Medication Rules)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Post-Hoc Analysis With Revised Restricted Medication Rules)408379
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.515 (Nominal p-value) · Mean difference (final values): 3.3 · 95% CI -6.7 to 13.4
SecondaryAnnualized Flare Rate

A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment.

Time frame:
Baseline to Week 52
Reported as:
Number · Annualized flare rate ratio
Annualized Flare Rate
Annualized flare rate ratioAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Annualized Flare Rate0.620.600.72
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Negative binomial regression · p = 0.258 (Nominal p-value) · Rate ratio: 0.83 · 95% CI 0.60 to 1.14
SecondaryNumber of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Original Analysis With Restricted Medication Rules)

A BICLA responder was achieved if all of the following criteria was met: All criteria related to SRI(4) (please see primary endpoint) plus: Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Original Analysis With Restricted Medication Rules)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Original Analysis With Restricted Medication Rules)276749
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · Mean difference (final values): 10.1 · 95% CI 0.6 to 19.7
Post-hocNumber of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Post-Hoc Analysis With Revised Restricted Medication Rules)

A BICLA responder was achieved if all of the following criteria was met: All criteria related to SRI(4) (please see primary endpoint) plus: Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment. Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Post-Hoc Analysis With Revised Restricted Medication Rules)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Post-Hoc Analysis With Revised Restricted Medication Rules)358354
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · Mean difference (final values): 16.4 · 95% CI 6.7 to 26.2
SecondaryNumber of Participants Reporting One or More Adverse Events (AE)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs.

Time frame:
Baseline to End of Trial (Maximum of 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants Reporting One or More Adverse Events (AE)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants Reporting One or More Adverse Events (AE)80161145
SecondaryNumber of Participants Reporting One or More Adverse Events of Special Interest (AESI)

An AESI is an AE of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by the Investigator to the Sponsor/Sponsor's delegate. An AESI may be serious or nonserious. The events of interest are serious infections, including non opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, TB (including latent TB), influenza, vasculitis (non-SLE), and MACE (including stroke, MI, or cardiovascular death). AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

Time frame:
Baseline to End of Trial (Maximum of 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants Reporting One or More Adverse Events of Special Interest (AESI)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants Reporting One or More Adverse Events of Special Interest (AESI)112318
SecondaryNumber of Participants With Markedly Abnormal Vital Signs

Vital signs included oral temperature, blood pressure (BP), pulse rate, and respiratory rate. Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

Time frame:
Baseline to End of Trial (Maximum of 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Vital Signs
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants With Markedly Abnormal Vital Signs143646
SecondaryNumber of Participants With Markedly Abnormal Physical Examinations

Physical examinations included height and weight. Participants were weighed at each study visit and any medically significant changes were reported. Physical examination values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

Time frame:
Baseline to End of Trial (Maximum of 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Physical Examinations
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants With Markedly Abnormal Physical Examinations322
SecondaryNumber of Participants With Markedly Abnormal Electrocardiogram (ECG) Scores

ECGs documented the date, time, heart rate, QRS duration, PR interval, RR interval, QT, and corrected QT interval, which were calculated using the Fridericia formula. The investigator judged the overall interpretation as normal or abnormal, and if abnormal it was decided as to whether or not the abnormality was clinically significant or not clinically significant.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Scores
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Scores000
SecondaryNumber of Participants With Mild To Moderate Lupus Flare Evaluated by Modified Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI Flare Index

The modified SELENA flare index was completed by the Investigator or delegated/qualified physician. Assessment of flares were scored in comparison to the participant's previous visit and should only include findings which, in the opinion of the Investigator, are due to systemic lupus erythematosus (SLE) disease activity within that timeframe. Flare was defined as any 1 criterion present in either the Mild/Moderate Flare or Severe Flare categories. Number of flares were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

Time frame:
Baseline to End of Trial (Maximum of 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Mild To Moderate Lupus Flare Evaluated by Modified Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI Flare Index
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants With Mild To Moderate Lupus Flare Evaluated by Modified Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI Flare Index385867
SecondaryNumber of Participants With Markedly Abnormal Laboratory Tests

Laboratory tests were collected at central clinical laboratories and included hematology, serum chemistry and urinalysis tests. Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

Time frame:
Baseline to End of Trial (Maximum of 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Laboratory Tests
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Number of Participants With Markedly Abnormal Laboratory Tests447187
SecondaryNumber of Participants With Suicidal Ideation or Behaviour Assessed Via the Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Number of participants with suicidal ideation or behavior was defined as the number of participants who answered "yes" at any time during the treatment period (Baseline to Week 52) to one of the 10 categories: Category 1: Wish to be dead Category 2: Non-specific active suicidal thoughts Category 3: Active suicidal ideation with any methods (not plan) without intent to act Category 4: Active suicidal ideation with some intent to act, without specific plan Category 5: Active suicidal ideation with specific plan and intent Category 6: Preparatory acts or behavior Category 7: Aborted attempt Category 8: Interrupted attempt Category 9: Actual attempt (non-fatal) Category 10: Completed suicide

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation or Behaviour Assessed Via the Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Suicidal ideation122
Suicidal behaviour001
SecondaryChange From Baseline in Personal Health Questionnaire Depression Scale-8 (PHQ-8) Score

PHQ-8 is a 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQ-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms. A negative change from baseline score indicates improvement in symptoms.

Time frame:
Baseline to Week 52
Reported as:
Mean · Score on a Scale
Change From Baseline in Personal Health Questionnaire Depression Scale-8 (PHQ-8) Score
Score on a ScaleAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Change From Baseline in Personal Health Questionnaire Depression Scale-8 (PHQ-8) Score-2.1 ± 4.43-2.7 ± 5.58-1.7 ± 5.40

Adverse events

Collected over Baseline to End of Trial (Maximum of 60 weeks post first dose). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anifrolumab 150 mg0/93 (0%)10/93 (10.8%)78/93 (83.9%)
Anifrolumab 300 mg1/180 (0.6%)27/180 (15%)157/180 (87.2%)
Placebo1/184 (0.5%)35/184 (19%)141/184 (76.6%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders2/934/1805/184
PneumoniaInfections and infestations1/933/1801/184
AsthmaRespiratory, thoracic and mediastinal disorders0/932/1801/184
Chest painGeneral disorders0/932/1800/184
Urinary tract infectionInfections and infestations1/931/1802/184
Atrial fibrillationCardiac disorders0/930/1802/184
Lupus nephritisRenal and urinary disorders0/930/1802/184
GangreneInfections and infestations1/930/1800/184
SepsisInfections and infestations1/930/1801/184
Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/930/1800/184
Most frequent other events
Showing 10 of 74
Most frequent other events
EventAnifrolumab 150 mgAnifrolumab 300 mgPlacebo
NasopharyngitisInfections and infestations15/9336/18024/184
Upper respiratory tract infectionInfections and infestations17/9322/18019/184
Urinary tract infectionInfections and infestations8/9322/18026/184
HeadacheNervous system disorders6/9317/18018/184
Infusion related reactionInjury, poisoning and procedural complications9/9316/18013/184
DiarrhoeaGastrointestinal disorders8/936/18014/184
BronchitisInfections and infestations7/9315/1809/184
NauseaGastrointestinal disorders3/939/18014/184
DepressionPsychiatric disorders7/936/1805/184
PharyngitisInfections and infestations6/9312/18013/184

Baseline characteristics

Full analysis set - all randomized participants who received at least one dose of investigational product.

Age, Continuous
Age, Continuous(Years)Anifrolumab 150 mgAnifrolumab 300 mgPlaceboTotal
Mean40.8 ± 12.0542.0 ± 11.9941.0 ± 12.3041.3 ± 12.11
Age, Customized
Age, Customized(Participants)Anifrolumab 150 mgAnifrolumab 300 mgPlaceboTotal
< 180000
≥ 18 to < 6590169178437
≥ 65311620
Sex: Female, Male
Sex: Female, Male(Participants)Anifrolumab 150 mgAnifrolumab 300 mgPlaceboTotal
Female86165171422
Male7151335
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Anifrolumab 150 mgAnifrolumab 300 mgPlaceboTotal
Hispanic or Latino20323587
Not Hispanic or Latino73148149370
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Anifrolumab 150 mgAnifrolumab 300 mgPlaceboTotal
American Indian or Alaska Native0011
Asian811524
Native Hawaiian or Other Pacific Islander0000
Black or African American14292366
White64125137326
More than one race0000
Unknown or Not Reported7151840
Height
Height(cm)Anifrolumab 150 mgAnifrolumab 300 mgPlaceboTotal
Mean164.02 ± 8.208162.99 ± 7.829163.10 ± 8.030163.24 ± 7.980
Weight
Weight(kg)Anifrolumab 150 mgAnifrolumab 300 mgPlaceboTotal
Mean73.57 ± 19.46975.36 ± 20.34374.69 ± 19.33274.72 ± 19.731
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m2)Anifrolumab 150 mgAnifrolumab 300 mgPlaceboTotal
Mean27.31 ± 6.8128.25 ± 6.89928.09 ± 7.14528.00 ± 6.976
08

Study locations

146 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    El Cajon, California 91942-3191, United States
  • Research Site
    La Jolla, California 92037-0706, United States
  • Research Site
    Los Alamitos, California 90720, United States
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Aventura, Florida 33180, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Ormond Beach, Florida 32174, United States
  • Research Site
    Plantation, Florida 33324, United States
  • Research Site
    Tampa, Florida 33614, United States
  • Research Site
    Vero Beach, Florida 32960, United States
  • Research Site
    Decatur, Georgia 30033, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Marietta, Georgia 30060, United States
  • Research Site
    Boise, Idaho 83712, United States
  • Research Site
    Idaho Falls, Idaho 83404, United States
  • Research Site
    Baton Rouge, Louisiana 70809, United States
  • Research Site
    Hagerstown, Maryland 21502, United States
  • Research Site
    Hagerstown, Maryland 21740, United States
  • Research Site
    Grand Rapids, Michigan 49546, United States
  • Research Site
    Minneapolis, Minnesota 55455-0341, United States
  • Research Site
    Nashua, New Hampshire 03060, United States
  • Research Site
    Freehold, New Jersey 07728, United States
  • Research Site
    Great Neck, New York 11021, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Charlotte, North Carolina 28210, United States
  • Research Site
    Raleigh, North Carolina 27617, United States
  • Research Site
    Cleveland, Ohio 44109, United States
  • Research Site
    Middleburg Heights, Ohio 44130, United States
  • Research Site
    Oklahoma City, Oklahoma 73101, United States
  • Research Site
    Tulsa, Oklahoma 74104, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Pittsburgh, Pennsylvania 15224, United States
  • Research Site
    Wyomissing, Pennsylvania 19610, United States
  • Research Site
    Charleston, South Carolina 29406, United States
  • Research Site
    Charleston, South Carolina 29407, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Jackson, Tennessee 38305, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Amarillo, Texas 79124, United States
  • Research Site
    Austin, Texas 78731, United States
  • Research Site
    Austin, Texas 78745, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    Mesquite, Texas 75150, United States
  • Research Site
    San Antonio, Texas 78232, United States
  • Research Site
    Glendale, Wisconsin 53217, United States
  • Research Site
    Cordoba, X5004AUL, Argentina
  • Research Site
    San Miguel de Tucuman, T4000AXL, Argentina
  • Research Site
    Fitzroy, 3065, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Belo Horizonte, 30150-221, Brazil
  • Research Site
    Juiz de Fora, 36010-570, Brazil
  • Research Site
    Porto Alegre, 90560-030, Brazil
  • Research Site
    Salvador, 40150-150, Brazil
  • Research Site
    Osorno, 5311092, Chile
  • Research Site
    Santiago, 8320000, Chile
  • Research Site
    Vina del Mar, 2520997, Chile
  • Research Site
    Armenia, 630004, Colombia
  • Research Site
    Barranquilla, 0, Colombia
  • Research Site
    Bogota, 110221, Colombia
  • Research Site
    Bogota, 111211, Colombia
  • Research Site
    Bucaramanga, 680003, Colombia
  • Research Site
    Medellin, 050021, Colombia
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Dessau-RoBlau, 06847, Germany
  • Research Site
    Frankfurt am Main, 60528, Germany
  • Research Site
    Göttingen, 37075, Germany
  • Research Site
    Kirchheim, 73230, Germany
  • Research Site
    Köln, 50937, Germany
  • Research Site
    Budapest, 1097, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Szeged, 6725, Hungary
  • Research Site
    Zalaegerszeg, 8900, Hungary
  • Research Site
    Haifa, 31048, Israel
  • Research Site
    Haifa, 3109601, Israel
  • Research Site
    Jerusalem, 9122001, Israel
  • Research Site
    Kfar Saba, 49281, Israel
  • Research Site
    Petach-Tikva, 49100, Israel
  • Research Site
    Tel Aviv, 64239, Israel
  • Research Site
    Milano, 20132, Italy
  • Research Site
    Milano, 20157, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Daejeon, 301-721, Korea, Republic of
  • Research Site
    Gwangju, 61469, Korea, Republic of
  • Research Site
    Jeonju-si, 54907, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 150-713, Korea, Republic of
  • Research Site
    Suwon-si, 61469, Korea, Republic of
  • Research Site
    Hamilton, 3204, New Zealand
  • Research Site
    Wellington, 6021, New Zealand
  • Research Site
    Arequipa, 54, Peru
  • Research Site
    Lima, 15023, Peru
  • Research Site
    Lima, 15033, Peru

Showing the first 100 of 146 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bruce IN, van Vollenhoven RF, Morand EF, Furie RA, Manzi S, White WB, Abreu G, Tummala R. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials. Rheumatology (Oxford). 2023 Apr 3;62(4):1526-1534. doi: 10.1093/rheumatology/keac491. PubMed 36018235 ↗
  • Bruce IN, Furie RA, Morand EF, Manzi S, Tanaka Y, Kalunian KC, Merrill JT, Puzio P, Maho E, Kleoudis C, Albulescu M, Hultquist M, Tummala R. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis. 2022 Jul;81(7):962-969. doi: 10.1136/annrheumdis-2021-221847. Epub 2022 May 17. PubMed 35580976 ↗
  • Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022 Jul;81(7):951-961. doi: 10.1136/annrheumdis-2021-221425. Epub 2022 Mar 25. PubMed 35338035 ↗
  • Loncharich MF, Anderson CW. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. ACR Open Rheumatol. 2022 Jun;4(6):486-491. doi: 10.1002/acr2.11414. Epub 2022 Feb 14. PubMed 35157371 ↗
  • Chia YL, Zhang J, Tummala R, Rouse T, Furie RA, Morand EF. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022 May 5;61(5):1900-1910. doi: 10.1093/rheumatology/keab704. PubMed 34528084 ↗
  • Furie R, Morand EF, Askanase AD, Vital EM, Merrill JT, Kalyani RN, Abreu G, Pineda L, Tummala R. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus. 2021 Jul;30(8):1254-1263. doi: 10.1177/09612033211014267. Epub 2021 May 12. PubMed 33977796 ↗
  • Furie R, Morand EF, Bruce IN, Isenberg D, van Vollenhoven R, Abreu G, Pineda L, Tummala R. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials. Arthritis Rheumatol. 2021 Nov;73(11):2059-2068. doi: 10.1002/art.41778. Epub 2021 Sep 22. PubMed 33913260 ↗
  • Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. PubMed 33687069 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Jul 2018, 37 months.

Results were first posted in Dec 2019, 1 year 4 months after primary completion. A results delay was requested in May 2019.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2015
First posted
May 18, 2015
StartActual
Jun 9, 2015
Primary completionActual
Jul 17, 2018
CompletionActual
Jul 17, 2018
Results delay requested
May 31, 2019
Results first posted
Dec 5, 2019
Last update
Jan 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02446912
Lead sponsor
AstraZeneca
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
May 18, 2015
Start date
Jun 9, 2015
Primary completion
Jul 17, 2018
Completion
Jul 17, 2018
Results posted
Dec 5, 2019
Last update
Jan 12, 2023

Study contacts

Herbert Hutman, MD
study director · Medical Science Director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion